{
    "clinical_study": {
        "@rank": "65629", 
        "arm_group": [
            {
                "arm_group_label": "Letrozole", 
                "arm_group_type": "Active Comparator", 
                "description": "Letrozole 2.5 mg daily"
            }, 
            {
                "arm_group_label": "Anastrozole", 
                "arm_group_type": "Active Comparator", 
                "description": "Anastrozole 1 mg daily"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to determine if there are differences in the final height or\n      hormone profile of short pubertal boys placed on different forms of aromatase inhibitor now\n      routinely used to increase stature: Anastrozole and Letrozole. It also should determine if\n      there are differences in the side effect profiles of the two drugs to be used."
        }, 
        "brief_title": "Aromatase Inhibitor Growth Study: Letrozole vs. Anastrozole", 
        "condition": "Short Stature", 
        "condition_browse": {
            "mesh_term": "Dwarfism"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Current height less than 5th percentile AND/OR\n\n          -  Predicted adult height (based on bone age) more than 10 cm below target height (mid\n             parental height)\n\n          -  Evidence of puberty: physical signs and serum luteinizing hormone > 0.3 IU/L and\n             testosterone > 15 ng/dl\n\n        Exclusion Criteria:\n\n          -  Bone age reading more than 14.0 years\n\n          -  Follicle stimulating hormone > 20 IU/L"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "10 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 5, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02137538", 
            "org_study_id": "AI growth study"
        }, 
        "intervention": [
            {
                "arm_group_label": "Letrozole", 
                "intervention_name": "Letrozole", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Anastrozole", 
                "intervention_name": "Anastrozole", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Letrozole", 
                "Anastrozole", 
                "Aromatase Inhibitors"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 8, 2014", 
        "location": {
            "contact": {
                "last_name": "E Kirk Neely, MD", 
                "phone": "650-723-5791"
            }, 
            "facility": {
                "address": {
                    "city": "Palo Alto", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94301"
                }, 
                "name": "Lucile Packard Children's Hospital"
            }, 
            "investigator": {
                "last_name": "E Kirk Neely, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomization to Letrozole vs. Anastrozole in Short Pubertal Males", 
        "overall_contact": {
            "email": "neely@stanford.edu", 
            "last_name": "E Kirk Neely, MD", 
            "phone": "650 723-5791"
        }, 
        "overall_official": {
            "affiliation": "Stanford University", 
            "last_name": "E Kirk Neely, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "November 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Heights will be obtained at physical exam every 6 months during treatment and annually until final height.", 
            "measure": "Adult height", 
            "safety_issue": "No", 
            "time_frame": "10 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02137538"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Baseline and 2 years", 
                "measure": "Bone density", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Baseline and 2 years", 
                "measure": "Spine x-ray", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Bone ages will be obtained at baseline and annually during therapy. to calculate interim predicted adult heights.", 
                "measure": "Change in bone age", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "description": "At baseline, every 6 months, and 1 year post-treatment, we will obtain serum levels of testosterone", 
                "measure": "testosterone", 
                "safety_issue": "No", 
                "time_frame": "0.5 to 4 years"
            }, 
            {
                "description": "At baseline, every 6 months, and 1 year post-treatment, we will obtain serum levels of dihydrotestosterone", 
                "measure": "dihydrotestosterone", 
                "safety_issue": "No", 
                "time_frame": "0.5 to 4 years"
            }, 
            {
                "description": "At baseline, every 6 months, and 1 year post-treatment, we will obtain serum levels of androstenedione", 
                "measure": "androstenedione", 
                "safety_issue": "No", 
                "time_frame": "0.5 to 4 years"
            }, 
            {
                "description": "At baseline, every 6 months, and 1 year post-treatment, we will obtain serum levels of estradiol", 
                "measure": "estradiol", 
                "safety_issue": "No", 
                "time_frame": "0.5 to 4 years"
            }, 
            {
                "description": "At baseline, every 6 months, and 1 year post-treatment, we will obtain serum levels of estrone", 
                "measure": "estrone", 
                "safety_issue": "No", 
                "time_frame": "0.5 to 4 years"
            }, 
            {
                "description": "At baseline, every 6 months, and 1 year post-treatment, we will obtain serum levels of inhibin B", 
                "measure": "inhibin B", 
                "safety_issue": "No", 
                "time_frame": "0.5 to 4 years"
            }, 
            {
                "description": "At baseline, every 6 months, and 1 year post-treatment, we will obtain serum levels of luteinizing hormone", 
                "measure": "luteinizing hormone", 
                "safety_issue": "No", 
                "time_frame": "0.5 to 4 years"
            }, 
            {
                "description": "At baseline, every 6 months, and 1 year post-treatment, we will obtain serum levels of follicle stimulating hormone", 
                "measure": "follicle stimulating hormone", 
                "safety_issue": "No", 
                "time_frame": "0.5 to 4 years"
            }, 
            {
                "description": "At baseline, every 6 months, and 1 year post-treatment, we will obtain serum levels of insulin-like growth factor 1", 
                "measure": "insulin-like growth factor 1", 
                "safety_issue": "No", 
                "time_frame": "0.5 to 4 years"
            }, 
            {
                "description": "At baseline, every 6 months, and 1 year post-treatment, we will obtain serum levels of insulin-like growth factor binding protein 3", 
                "measure": "insulin-like growth factor binding protein 3", 
                "safety_issue": "No", 
                "time_frame": "0.5 to 4 years"
            }
        ], 
        "source": "Stanford University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Stanford University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2009", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}